Stay updated on Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial

Sign up to get notified when there's something new on the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    Entries were added to the Study Record Dates section to capture the latest submission and posting dates, as well as a completion date. These updates reflect the current activity and status of the study record.
    Difference
    0.3%
    Check dated 2026-05-22T09:50:01.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    Revision metadata on the page was updated from v3.5.3 to v3.5.4, reflecting a routine update to the page version.
    Difference
    0.1%
    Check dated 2026-05-15T06:28:11.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The study status is updated to Completed with a completion date of 2026-04-30 and a last update date of 2026-05-01, and the previous 'Active, not recruiting' status has been removed.
    Difference
    0.5%
    Check dated 2026-05-08T10:00:51.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    The page’s interface/build version was updated from v3.5.2 to v3.5.3 without changing the displayed study details.
    Difference
    0.1%
    Check dated 2026-04-24T06:39:48.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    - Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.1%
    Check dated 2026-04-17T02:50:45.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    Added a link to the Genetic and Rare Diseases Information Center resources for squamous cell carcinoma of the head and neck, and a related topic entry for head and neck squamous cell carcinoma.
    Difference
    0.2%
    Check dated 2026-04-02T15:36:16.000Z thumbnail image

Stay in the know with updates to Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page.